

**Supplemental Table 2.****Individual drug characteristics and doses, maximum plasma levels and protein binding of panobinostat and belinostat in the two phase 1 studies**

Study	Drug	Chemical structure	Dose	Activity	Cmax	Protein binding
Phase 1 Belinostat Part 1 (Agarwal et al., 2016)	Belinostat	Hydroxamic acid	1000 mg/m <sup>2</sup> IV	Class I,II, IV	150±31.6 (uM)	93-96%
Phase 1 Belinostat (Bailey et al., 2016)	Belinostat	Hydroxamic acid		Class I,II, IV	131±31.6 (uM)	93-96%
Phase 1 Panobinostat Sharma et al., 2015)	Panobinostat	Hydroxamic acid	30 mg orally	Class I, II, IV	31 ng/ml*	82-88%

Cmax= maximum plasma concentration;

\*for normal renal function CrCL ≥ 80 mL/min